Toggle navigation
Home
Search
Services
Blog
Contact
About
Rational Design of Neuropeptide Y Therapeutics
Salon, John A.
Synaptic Pharmaceutical Corporation, Paramus, NJ, United States
Search 7 grants from John Salon
Search grants from Synaptic Pharmaceutical Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
30th Biennial Cornea Conference
The CYGNET Study: Enviromental and Genetic Determinants of Maturation of Girls
Pax Gene Transcription Regulation in Early Embryogenesis
Training in Allergy and Immunology
Conference Grant: Student Travel Awards for the 15th International Workshop on Computational Electronics (IWCE 2012). To be held May 22-25 at University of Wisconsin Madison
Recently added grants:
Mechanisms of posttranscriptional regulation of SAM homeostasis
Peroxisome biogenesis, dynamics, and degradation
Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms
Protein Mechanics Regulating Endocytic Clathrin Coat Nucleation
Studies on Enzyme Activation and Novel Modes of Inhibition
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44NS031843-03
Application #
2269799
Study Section
Special Emphasis Panel (ZRG7-SSS-Z (13))
Project Start
1994-09-01
Project End
1996-08-31
Budget Start
1995-09-01
Budget End
1996-08-31
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Synaptic Pharmaceutical Corporation
Department
Type
DUNS #
City
Paramus
State
NJ
Country
United States
Zip Code
07652
Related projects
NIH 1995
R44 NS
Rational Design of Neuropeptide Y Therapeutics
Salon, John A. / Synaptic Pharmaceutical Corporation
NIH 1994
R44 NS
Rational Design of Neuropeptide Y Therapeutics
Salon, John A. / Synaptic Pharmaceutical Corporation
Comments
Be the first to comment on this grant